Last reviewed · How we verify
Active comparator2 : Telmisartan
Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Cardiovascular risk reduction in patients with hypertension.
At a glance
| Generic name | Active comparator2 : Telmisartan |
|---|---|
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and improved renal perfusion. This mechanism also provides cardioprotective and renoprotective effects in hypertensive and diabetic patients.
Approved indications
- Hypertension
- Cardiovascular risk reduction in patients with hypertension
Common side effects
- Dizziness
- Upper respiratory tract infection
- Back pain
- Pharyngitis
- Hyperkalemia
- Hypotension
Key clinical trials
- Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension (PHASE2)
- To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |